CN109311908A - 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 - Google Patents
作为Akt抑制剂的二氢吡唑氮杂卓类化合物 Download PDFInfo
- Publication number
- CN109311908A CN109311908A CN201780037686.3A CN201780037686A CN109311908A CN 109311908 A CN109311908 A CN 109311908A CN 201780037686 A CN201780037686 A CN 201780037686A CN 109311908 A CN109311908 A CN 109311908A
- Authority
- CN
- China
- Prior art keywords
- milligrams
- lcms
- esi
- milliliters
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (11)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610428049 | 2016-06-16 | ||
CN2016104280496 | 2016-06-16 | ||
CN201610674021 | 2016-08-15 | ||
CN2016106740210 | 2016-08-15 | ||
PCT/CN2017/088030 WO2017215588A1 (zh) | 2016-06-16 | 2017-06-13 | 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109311908A true CN109311908A (zh) | 2019-02-05 |
CN109311908B CN109311908B (zh) | 2021-05-07 |
Family
ID=60663995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780037686.3A Active CN109311908B (zh) | 2016-06-16 | 2017-06-13 | 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10654868B2 (zh) |
EP (1) | EP3473628B1 (zh) |
JP (1) | JP6900406B2 (zh) |
KR (1) | KR102351270B1 (zh) |
CN (1) | CN109311908B (zh) |
WO (1) | WO2017215588A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111433213A (zh) * | 2017-12-13 | 2020-07-17 | 哈尔滨珍宝制药有限公司 | 作为Akt抑制剂的盐型及其晶型 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022121788A1 (zh) * | 2020-12-07 | 2022-06-16 | 南京正大天晴制药有限公司 | 一种吡唑并氮杂卓类akt抑制剂 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1639151A (zh) * | 2002-03-12 | 2005-07-13 | 霍夫曼-拉罗奇有限公司 | 新的氮杂环庚烷衍生物 |
CN101094833A (zh) * | 2004-07-12 | 2007-12-26 | 伊邓药品公司 | 四肽类似物 |
WO2008065054A1 (en) * | 2006-11-28 | 2008-06-05 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
WO2008098104A1 (en) * | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
EP2002836A1 (en) * | 2007-05-31 | 2008-12-17 | Nerviano Medical Sciences S.r.l. | Cyclocondensed azaindoles active as kinase inhibitors |
WO2009089305A1 (en) * | 2008-01-07 | 2009-07-16 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
CN103298461A (zh) * | 2010-11-17 | 2013-09-11 | 霍夫曼-拉罗奇有限公司 | 治疗肿瘤的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525928A (ja) | 2008-06-26 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Akt活性の阻害剤 |
-
2017
- 2017-06-13 EP EP17812699.1A patent/EP3473628B1/en active Active
- 2017-06-13 JP JP2018565750A patent/JP6900406B2/ja active Active
- 2017-06-13 WO PCT/CN2017/088030 patent/WO2017215588A1/zh unknown
- 2017-06-13 CN CN201780037686.3A patent/CN109311908B/zh active Active
- 2017-06-13 KR KR1020197001396A patent/KR102351270B1/ko active IP Right Grant
- 2017-06-13 US US16/309,648 patent/US10654868B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1639151A (zh) * | 2002-03-12 | 2005-07-13 | 霍夫曼-拉罗奇有限公司 | 新的氮杂环庚烷衍生物 |
CN101094833A (zh) * | 2004-07-12 | 2007-12-26 | 伊邓药品公司 | 四肽类似物 |
WO2008065054A1 (en) * | 2006-11-28 | 2008-06-05 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
WO2008098104A1 (en) * | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
EP2002836A1 (en) * | 2007-05-31 | 2008-12-17 | Nerviano Medical Sciences S.r.l. | Cyclocondensed azaindoles active as kinase inhibitors |
WO2009089305A1 (en) * | 2008-01-07 | 2009-07-16 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
CN103298461A (zh) * | 2010-11-17 | 2013-09-11 | 霍夫曼-拉罗奇有限公司 | 治疗肿瘤的方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111433213A (zh) * | 2017-12-13 | 2020-07-17 | 哈尔滨珍宝制药有限公司 | 作为Akt抑制剂的盐型及其晶型 |
CN111433213B (zh) * | 2017-12-13 | 2023-03-10 | 哈尔滨珍宝制药有限公司 | 作为Akt抑制剂的盐型及其晶型 |
Also Published As
Publication number | Publication date |
---|---|
KR20190017996A (ko) | 2019-02-20 |
CN109311908B (zh) | 2021-05-07 |
JP2019518052A (ja) | 2019-06-27 |
US10654868B2 (en) | 2020-05-19 |
EP3473628A4 (en) | 2019-05-01 |
US20190233434A1 (en) | 2019-08-01 |
EP3473628A1 (en) | 2019-04-24 |
EP3473628B1 (en) | 2019-12-11 |
WO2017215588A1 (zh) | 2017-12-21 |
JP6900406B2 (ja) | 2021-07-07 |
KR102351270B1 (ko) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102615733B1 (ko) | 항암제로서의 치환 2-h-피라졸 유도체 | |
EP3080100B1 (en) | Inhibitors of lysine specific demethylase-1 | |
CN105121432B (zh) | 作为激酶抑制剂的杂环酰胺 | |
CN112055709A (zh) | 吡嗪化合物和其用途 | |
CN108659005B (zh) | 作为egfr抑制剂的喹唑啉衍生物 | |
CN107531695A (zh) | Jak抑制剂 | |
CN108349977A (zh) | Jak抑制剂 | |
CN110062758A (zh) | 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物 | |
CN104837829A (zh) | 抑制剂化合物 | |
CN110198943A (zh) | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 | |
CN105461712B (zh) | 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 | |
CN106470992B (zh) | 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 | |
EP2678315B1 (en) | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR | |
CN107922349A (zh) | 作为fgfr和vegfr抑制剂的乙烯基化合物 | |
EP3971190A1 (en) | Heterocycle-fused pyrimidine derivative and use thereof | |
CN114401955A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
CN111683928A (zh) | 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 | |
EP4079734A1 (en) | Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
CN111655689B (zh) | 吡唑并吡啶酮化合物 | |
CN102459278A (zh) | 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮 | |
Guerrini et al. | Synthesis and pharmacological evaluation of pyrazolo [1, 5-a] pyrimidin-7 (4H)-one derivatives as potential GABAA-R ligands | |
CN109311908A (zh) | 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 | |
CN107709323A (zh) | 羟基嘌呤类化合物及其应用 | |
CN111655690A (zh) | 吡唑并吡啶酮化合物 | |
CN111747954B (zh) | 吡嗪化合物和其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province Applicant after: Nanjing Mingde New Drug Development Co.,Ltd. Address before: 210032 Jiangsu city of Nanjing province Nanjing high tech Development Zone of High Road No. 9 business office building room 218 Applicant before: MEDSHINE DISCOVERY Inc. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190816 Address after: 150060 Yantai No. 8 Pharmaceutical Research Institute, Harbin Development Zone, Heilongjiang Province Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd. Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province Applicant before: Nanjing Mingde New Drug Development Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |